Assenagon Asset Management S.A. reduced its position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) by 0.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 601,005 shares of the biotechnology company's stock after selling 5,264 shares during the period. Assenagon Asset Management S.A. owned approximately 0.64% of Atara Biotherapeutics worth $2,272,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ATRA. Diversified Trust Co purchased a new position in Atara Biotherapeutics in the 3rd quarter valued at about $48,000. Wealth Architects LLC purchased a new position in Atara Biotherapeutics in the 3rd quarter valued at about $50,000. Denali Advisors LLC purchased a new position in Atara Biotherapeutics in the 3rd quarter valued at about $50,000. Point72 Hong Kong Ltd boosted its position in Atara Biotherapeutics by 343.8% in the 1st quarter. Point72 Hong Kong Ltd now owns 7,234 shares of the biotechnology company's stock valued at $67,000 after buying an additional 5,604 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Atara Biotherapeutics during the second quarter worth about $106,000.
Get Atara Biotherapeutics alerts:Insider Buying and Selling
In other Atara Biotherapeutics news, CEO Pascal Touchon sold 15,591 shares of the firm's stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total value of $70,003.59. Following the sale, the chief executive officer now owns 441,696 shares in the company, valued at $1,983,215.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Atara Biotherapeutics news, CEO Pascal Touchon sold 15,591 shares of the firm's stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total value of $70,003.59. Following the sale, the chief executive officer now owns 441,696 shares in the company, valued at $1,983,215.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Utpal Koppikar sold 6,255 shares of the firm's stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total transaction of $28,084.95. Following the completion of the sale, the chief financial officer now owns 191,334 shares in the company, valued at approximately $859,089.66. The disclosure for this sale can be found here. Insiders have sold a total of 29,800 shares of company stock worth $133,802 over the last quarter. 4.00% of the stock is owned by company insiders.
Analyst Ratings Changes
Several equities analysts have recently commented on the stock. StockNews.com assumed coverage on shares of Atara Biotherapeutics in a research report on Wednesday, October 12th. They set a "hold" rating on the stock. EF Hutton Acquisition Co. I assumed coverage on shares of Atara Biotherapeutics in a research report on Thursday, January 5th. They set a "buy" rating and a $25.00 price target on the stock. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Atara Biotherapeutics has a consensus rating of "Hold" and an average price target of $19.50.Atara Biotherapeutics Stock Up 1.1 %
ATRA opened at $3.66 on Thursday. The firm has a market cap of $347.26 million, a price-to-earnings ratio of -1.48 and a beta of 1.08. Atara Biotherapeutics, Inc. has a fifty-two week low of $2.83 and a fifty-two week high of $16.35. The company's 50-day moving average price is $4.01 and its 200 day moving average price is $4.38.
Atara Biotherapeutics Company Profile
(Get Rating)
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.
Read More
- Get a free copy of the StockNews.com research report on Atara Biotherapeutics (ATRA)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating).
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.